RBC Capital Markets Advises Tolmar on Acquisition of JATENZO from Clarus Therapeutics
Tolmar Pharmaceuticals, a fully integrated pharmaceutical company, through its affiliate, Tolmar, acquired of all rights to JATENZO from Clarus Therapeutics Holdings and its wholly-owned subsidiary Clarus Therapeutics.
October 31, 2022
Anil D'Souza | Clarus Therapeutics | Faegre Drinker Biddle & Reath | RBC Capital Markets | Todd Smith | Tolmar Pharmaceuticals
Ian Koplin